Mortality: all cancers · healthy women, aged 35 to 60, and men, aged 45 to 60, living in France
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality: all causes · healthy women, aged 35 to 60, and men, aged 45 to 60, living in France
Vitamins A, C, E + selenium + zinc showed no clear difference in mortality: all causes compared with placebo (high certainty).
1 finding from 1 review
Clinical efficacy ‐ improvement (> 40%) in ESRS scores from baseline ESRS1 · patients with antipsychotic‐induced tardive dyskinesia
Pyridoxal 5 phosphate (vitamin B6) may leads to higher clinical efficacy ‐ improvement (> 40%) in ESRS scores from baseline… compared with placebo (low certainty).
1 finding from 1 review
Global: Other adverse effects than tardive dyskinesia Self‐report by participants · patients with antipsychotic‐induced tardive dyskinesia
Pyridoxal 5 phosphate (vitamin B6) showed no clear difference in global: Other adverse effects than tardive dyskinesia Self‐report by… compared with placebo (low certainty).
1 finding from 1 review
Tardive dyskinesia: Deterioration of symptoms · patients with antipsychotic‐induced tardive dyskinesia
Pyridoxal 5 phosphate (vitamin B6) showed no clear difference in tardive dyskinesia: Deterioration in tardive dyskinesia symptoms ESRS1 compared with placebo (low certainty).
1 finding from 1 review
General mental state: Positive psychiatric symptom score PANSS5. Scale from: 7 to 49. · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
General mental state: Negative psychiatric symptoms PANSS5. Scale from: 7 to 49. · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Outcome: · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality at 6 months: main analysis · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Vitamin K antagonist (VKA) prophylaxis showed no clear difference in mortality at 6 months: main analysis compared with no prophylaxis (moderate certainty).
1 finding from 1 review
All‐cause mortality · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Vitamin K antagonist (VKA) prophylaxis showed no clear difference in mortality compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Pulmonary embolism · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
It is very uncertain whether vitamin K antagonist (VKA) prophylaxis changes pulmonary embolism compared with no prophylaxis (very low certainty).
1 finding from 1 review
Symptomatic DVT · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
It is very uncertain whether vitamin K antagonist (VKA) prophylaxis changes symptomatic deep vein thrombosis compared with no prophylaxis (very low certainty).
1 finding from 1 review
Major bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Vitamin K antagonist (VKA) prophylaxis probably leads to higher major bleeding compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Minor bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
Vitamin K antagonist (VKA) prophylaxis probably leads to higher minor bleeding compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Quality of life ‐ not reported · ambulatory people with cancer without venous thromboembolism receiving systemic therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent venous thromboembolism · people > 18 years of age with a diagnosed deep vein thrombosis
Fondaparinux plus vitamin K antagonist showed no clear difference in recurrent venous thromboembolism compared with standard therapy (moderate certainty).
1 finding from 1 review
Major bleeding · people > 18 years of age with a diagnosed deep vein thrombosis
Fondaparinux plus vitamin K antagonist showed no clear difference in major bleeding during the initial treatment compared with standard therapy (moderate certainty).
2 findings from 1 review
All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis
Fondaparinux plus vitamin K antagonist showed no clear difference in all‐cause mortality compared with standard therapy (moderate certainty).
1 finding from 1 review
Heparin‐induced thrombocytopenia ‐ not measured · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All harmful effects · people > 18 years of age with a diagnosed deep vein thrombosis
It is very uncertain whether fondaparinux plus vitamin K antagonist changes all harmful effects compared with standard therapy (very low certainty).
1 finding from 1 review